Polycystic Ovary Syndrome
Conditions
Brief summary
Metabolic profile in women of different body composition with polycystic ovary syndrome.
Detailed description
Will be performed case-control study with women with Polycystic Ovary Syndrome, according to the Rotterdam criteria and body mass index between 18 to 29.9. The control group will consist of women without Polycystic Ovary Syndrome, with a body mass index of 18 to 29.9 and no other comorbidities. In both groups collect anthropometric data such as age, weight, height, waist circumference and blood pressure. Exams will be requested: metabolic profile (total cholesterol (mg/dL) and fractions, triglycerides (mg/dL), blood count, liver function (U/L) and classical glycemic index (mg/dL); hormonal profile - insulin (uIU/ml), luteinizing hormone (IU/L), follicle stimulating hormone (IU/L), thyreostimulating hormone (uIU/ML), total and free testosterone (ng/ml), 17-hydroxyprogesterone (ng/ml), dehydroepiandrosterone (ng/ml), prolactin (ug/ml). Body composition (BMI) will be performed by absorption technique of two low energy beams emitted by X-ray - full body densitometry (DEXA). Expected result: To evaluate visceral fat and truncal of patients with diagnosis of Polycystic Ovary Syndrome without obesity.
Interventions
None listed
Sponsors
Irmandade da Santa Casa de Misericordia de Sao Paulo
Study design
Observational model
CASE_CROSSOVER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
FEMALE
Age
12 Years to 39 Years
Healthy volunteers
Yes
Inclusion criteria
* Polycystic Ovary Syndrome , body mass index of 18 to 29.9, without contraceptive use.
Exclusion criteria
* Hypothyroidism, hyperprolactinaemia (defined as serum prolactin levels greater than 25 ng/mL) * Cushing's syndrome * Nonclassical congenital adrenal hyperplasia (defined as serum 17-hydroxyprogesterone levels greater than 1.2 and 5.2 ng/mL in the follicular and luteal phase, respectively) and current or previous (within the last three months) use of oral contraceptives and other hormonal * Antidiabetic and antiobesity drugs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Metabolic profile | 12 months | total cholesterol (mg/dL) and fractions, triglycerides (mg/dL) will estimate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Liver function | 12 months | Liver function (U/L) will estimate |
| luteinizing hormone | 12 months | luteinizing hormone (IU/L) will estimate |
| Hormonal profile - insulin | 12 months | Hormonal profile - insulin (uIU/ml) will estimate |
| Follicle stimulating hormone | 12 months | Follicle stimulating hormone (IU/L) will estimate |
| thyreostimulating hormone | 12 months | thyreostimulating hormone (uIU/ML) will estimate |
| Classical glycemic index | 12 months | Classical glycemic index (mg/dL) will estimate |
| 17-hydroxyprogesterone | 12 months | 17-hydroxyprogesterone (ng/ml) will estimate |
| Dehydroepiandrosterone | 12 months | Dehydroepiandrosterone (ng/ml) will estimate |
| Prolactin | 12 months | Prolactin (ug/ml) will estimate |
| DEXA | 12 months | Body composition will measure by DEXA scan |
| Total and free testosterone | 12 months | Total and free testosterone (ng/ml) will estimate |
Countries
Brazil
Contacts
Primary ContactCarolina F Macruz, doctor
Backup ContactIrmandade Santa Casa Sao Paulo
Outcome results
None listed